Abiomed, Inc.ABMDNASDAQ
Loading
R&D Expense Growth Recovery in ProgressRecovering
Percentile Rank46
3Y CAGR+74.3%
5Y CAGR-22.8%
Year-over-Year Change
Year-over-year research & development expense growth
3Y CAGR
+74.3%/yr
vs -55.0%/yr prior
5Y CAGR
-22.8%/yr
Recent acceleration
Acceleration
+129.3pp
Accelerating
Percentile
P46
Within normal range
vs 5Y Ago
0.3x
Contraction
Streak
1 qtr
Consecutive growthRecovering
| Period | Value |
|---|---|
| Q3 2022 | 3.98% |
| Q2 2022 | -7.56% |
| Q1 2022 | 7.13% |
| Q4 2021 | -0.42% |
| Q3 2021 | 8.84% |
| Q2 2021 | 17.88% |
| Q1 2021 | -3.08% |
| Q4 2020 | 8.12% |
| Q3 2020 | 15.81% |
| Q2 2020 | 3.99% |
| Q1 2020 | -1.20% |
| Q4 2019 | 7.03% |
| Q3 2019 | 0.75% |
| Q2 2019 | -6.88% |
| Q1 2019 | 6.61% |
| Q4 2018 | 5.49% |
| Q3 2018 | 6.79% |
| Q2 2018 | 0.01% |
| Q1 2018 | 20.13% |
| Q4 2017 | -8.68% |
| Q3 2017 | 14.52% |
| Q2 2017 | 3.71% |
| Q1 2017 | -0.15% |
| Q4 2016 | -9.43% |
| Q3 2016 | 15.27% |
| Q2 2016 | 10.09% |
| Q1 2016 | 3.42% |
| Q4 2015 | 18.90% |
| Q3 2015 | 13.31% |
| Q2 2015 | 3.62% |
| Q1 2015 | 17.79% |
| Q4 2014 | -3.77% |
| Q3 2014 | -4.07% |
| Q2 2014 | 14.42% |
| Q1 2014 | 1.81% |
| Q4 2013 | 0.75% |
| Q3 2013 | 5.96% |
| Q2 2013 | 6.82% |
| Q1 2013 | 4843.48% |
| Q4 2012 | -97.64% |